Lung cancer: immunopathology

F. Pezzella, M. Trivella, K. C. Gatter

Source: Eur Respir Mon; 2001: 17: 48–60
Journal Issue: Lung Cancer

PDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Pezzella, M. Trivella, K. C. Gatter. Lung cancer: immunopathology. Eur Respir Mon; 2001: 17: 48–60

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pre-invasive diseases of the lung
Source: Eur Respir Mon; 2009: 44: 36–56
Year: 2009

Pathology and immunohistochemistry of lung cancer
Source: Eur Respir Mon; 2009: 44: 15–35
Year: 2009

Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy
Source: Eur Respir J 2012; 39: 1437-1442
Year: 2012



Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006


Epigenetics and lung cancer
Source: Annual Congress 2006 - Epigenetics and respiratory disease
Year: 2006


Markers of angiogenesis in serum are correlating with disease progress in lung cancer
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006


Staging of lung cancer
Source: Eur Respir Mon; 2009: 44: 150–168
Year: 2009

Evolution of microRNA expression during human bronchial squamous carcinogenesis
Source: Eur Respir J 2009; 33: 352-359
Year: 2009



Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma
Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma
Year: 2006


Procalitonin: A prognosis factor in lung cancer and a marker for small-cell lung cancer
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011

Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome in resected non-small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014


Lung cancer
Source: Respipedia Article
Year: 2018

Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013

MUC1 associates with smoking, prognosis and histological subtypes in lung adenocarcinoma
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015

Lung resistance-related protein in lung cancer and lung lesions in Hodgkin disease
Source: Eur Respir J 2006; 28: Suppl. 50, 86s
Year: 2006

Venothromboembolism in lung cancer
Source: Eur Respir J 2007; 30: Suppl. 51, 601s
Year: 2007

Aerosoltherapy in lung cancer
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008


Symptoms, signs and staging of lung cancer
Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=86
Year: 2001

Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013


Lung cancer: morphology
Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=34
Year: 2001